Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Carcinoma × cabazitaxel × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Prostatic Neoplasms 3 Neoplasms 2 Recurrence 1 Prostatic Neoplasms, Castration-Resistant 1 Oligodendroglioma 1 Metastatic Castration-resistant Prostate Cancer 1 Malignant Solid Tumor - Malignant Nervous System Neoplasm 1 Gliosarcoma 1 Glioma 1 Glioblastoma 1 Carcinoma 1 Brain Neoplasms 1 Astrocytoma 1

Interventions

pembrolizumab 11 Cetuximab 5 Paclitaxel 4 durvalumab 3 Nivolumab 3 Gemcitabine 3 Cyclophosphamide 3 Cisplatin 3 poly ICLC 2 avelumab 2 Irinotecan 2 Ipilimumab 2 Carboplatin 2 Albumin-Bound Paclitaxel 2 130-nm albumin-bound paclitaxel 2 vistusertib 1 tislelizumab 1 tirbanibulin 1 spartalizumab 1 sonidegib 1 sitravatinib 1 repotrectinib 1 pralsetinib 1 pertuzumab 1 pepinemab 1 obinutuzumab 1 mogamulizumab 1 lutetium Lu 177 dotatate 1 lenvatinib 1 gedatolisib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02202772 2025-02-24

CGC

Columbia University

Phase 1/2 Active not recruiting

Carcinoma, Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡